Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo

BACKGROUND: Resistance to HER2-targeted therapies, including the monoclonal antibody trastuzumab and tyrosine kinase inhibitor lapatinib, frequently occurs and currently represents a significant clinical challenge in the management of HER2-positive breast cancer. We previously showed that the trastu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao, Ruan, Sanbao, Larsen, Margaret E., Tan, Congcong, Liu, Bolin, Lyu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294508/
https://www.ncbi.nlm.nih.gov/pubmed/37370010
http://dx.doi.org/10.1186/s12575-023-00212-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294508/
https://www.ncbi.nlm.nih.gov/pubmed/37370010
http://dx.doi.org/10.1186/s12575-023-00212-3

Ejemplares similares